Harnessing AI to accelerate personalized cancer treatment
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, today announced its continued work with Movember, the leading charity changing the face of men’s health on a global scale.
“Being able to predict what might happen for men with aggressive prostate cancer is incredibly important”
“We are privileged to stand shoulder to shoulder with industry leaders in the battle against prostate cancer,” said Andre Esteva, CEO and co-founder of ArteraAI. “It is through strategic collaborations with those who share a passion for advancing how we treat this disease, that we will be able to harness AI to accelerate personalized cancer treatment.”
Recommended AI News: Tellius Reveals GenAI Enhancements, Pioneering Enterprise Analytics and Insights
This announcement follows a recent study presented at the 2023 European Society for Medical Oncology Congress (ESMO). The study successfully validated ArteraAI’s prognostic model in advanced prostate cancer, demonstrating stronger prognostic correlations than individual clinical factors. This study was a component of the broader STRATOSPHere project, initiated and funded by Movember and Prostate Cancer UK, an initiative to accelerate the progress of precision medicine by using data from tumor and blood samples of men participating in STAMPEDE, to identify biomarker-treatment pairings to personalize therapy.
ArteraAI looks forward to its continued work with these organizations as there are several ongoing initiatives in the early development phase.
Recommended AI News: Philips and SyntheticMR Collaboration Advances AI in MRI Diagnostic Imaging: GlobalData
“Being able to predict what might happen for men with aggressive prostate cancer is incredibly important,” said Sarah Hsiao, Director, Biomedical Research and Impact. “Movember is proud to have supported the STRATOSPHere team on this innovative research, leveraging ArteraAI’s technology to empower men with prostate cancer and their providers to make informed treatment decisions.”
Although prostate cancer is a common disease, it currently lags behind other cancers in terms of precision medicine advancements. This gap means that many men do not always receive the most suitable treatments, potentially leading to life-altering side effects or even fatal outcomes. While current guidelines provide general recommendations on how to treat prostate cancer, they are not personalized to the individual. Cancer is personal. Cancer therapy should be too.
Recommended AI News: Ryght Joins NVIDIA Inception to Accelerate GenAI Innovations in Life Sciences
[To share your insights with us as part of editorial or sponsored content, please write to sghosh@martechseries.com]
Comments are closed.